129 related articles for article (PubMed ID: 32718298)
21. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin And Angiogenic Factors As New Biomarkers Of Prostate Cancer.
Wisniewski T; Zyromska A; Makarewicz R; Zekanowska E
Urol J; 2019 May; 16(2):134-140. PubMed ID: 30178447
[TBL] [Abstract][Full Text] [Related]
24. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
25. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
[TBL] [Abstract][Full Text] [Related]
26. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
27. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
28. Osteoprotegerin and rank ligand expression in prostate cancer.
Brown JM; Corey E; Lee ZD; True LD; Yun TJ; Tondravi M; Vessella RL
Urology; 2001 Apr; 57(4):611-6. PubMed ID: 11306358
[TBL] [Abstract][Full Text] [Related]
29. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
Anborgh PH; Wilson SM; Tuck AB; Winquist E; Schmidt N; Hart R; Kon S; Maeda M; Uede T; Stitt LW; Chambers AF
Clin Chem; 2009 May; 55(5):895-903. PubMed ID: 19325010
[TBL] [Abstract][Full Text] [Related]
30. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
31. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
32. Osteopontin May Improve Postinjury Muscle Repair Via Matrix Metalloproteinases And tgf-β Activation in Regular Exercise.
Wang Y; Hong L; Jiang J; Zhang X; Chen J; Diao H
Int J Med Sci; 2023; 20(9):1202-1211. PubMed ID: 37575268
[TBL] [Abstract][Full Text] [Related]
33. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.
Karapanagiotou EM; Terpos E; Dilana KD; Alamara C; Gkiozos I; Polyzos A; Syrigos KN
Med Oncol; 2010 Jun; 27(2):332-8. PubMed ID: 19373566
[TBL] [Abstract][Full Text] [Related]
34. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
Ramankulov A; Lein M; Kristiansen G; Loening SA; Jung K
Prostate; 2007 Feb; 67(3):330-40. PubMed ID: 17192877
[TBL] [Abstract][Full Text] [Related]
35. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Koeneman KS; Yeung F; Chung LW
Prostate; 1999 Jun; 39(4):246-61. PubMed ID: 10344214
[TBL] [Abstract][Full Text] [Related]
36. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?
Ayan AK; Erdemci B; Orsal E; Bayraktutan Z; Akpinar E; Topcu A; Turkeli M; Seven B
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):102-6. PubMed ID: 26521996
[TBL] [Abstract][Full Text] [Related]
37. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
Brown JM; Vessella RL; Kostenuik PJ; Dunstan CR; Lange PH; Corey E
Clin Cancer Res; 2001 Oct; 7(10):2977-83. PubMed ID: 11595685
[TBL] [Abstract][Full Text] [Related]
38. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
40. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
